Is Vertex Pharmaceuticals Heading to $600? A new product approval may be right around the corner.
Better Nuclear Energy Stock: Oklo vs. Centrus Energy The two nuclear energy companies are in the early stages of discussing a joint venture to develop next-generation nuclear fuel, but one looks like a better buy today.
CBIZ Insider Sale: Trust Move or Warning Sign? CBIZ, Inc., a major business services provider, reported significant insider selling amid a year of sharp share price declines.
Battle of the Tech ETFs: How IYW and XLK Compare on Risk, Fees, and Performance Explore how differences in cost, diversification, and risk set these two tech ETFs apart for investors seeking tailored sector exposure.
Maxed Out Your IRA? Here's What to Do Next. You have a number of options if you're looking to save more.
The Best Stocks to Invest $1,000 in Right Now Given the market's uncertainty, now is a good time to err on the side of caution... and dividends.
IMAX CEO Sold Shares Worth $4.9 Million. Is the Stock a Buy or Sell? IMAX, a global leader in premium cinema technology, reported significant insider selling amid a year of strong stock performance.
Infrastructure Stock Up 67% This Past Year Just Drew a New $6 Million Investment This infrastructure contractor delivers large-scale civil projects and materials for public and private clients across the U.S.
SPXL vs. TQQQ: Is S&P 500 Stability or Tech-Focused Growth the Better Buy for Leveraged ETF Investors? Explore how sector exposure and risk profiles set these leveraged ETFs apart for traders seeking distinct portfolio dynamics.
Water Giant With $7 Billion in Revenue Draws $7.5 Million Investment, and Shares Are Surging This Year This water solutions provider serves both consumers and businesses through recurring sales and a broad portfolio of regional brands.
Payments Stock Down 30% Draws $6 Million Bet as Company Posts $4 Billion in Revenue Euronet Worldwide runs a global payments platform, providing transaction processing and money transfer solutions across diverse markets.
Is Signet Jewelers Seriously Undervalued? Shares of Signet Jewelers are up over 70% over the past year, limiting the value appeal of the stock as economic concerns hit consumers.
This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment EyePoint develops sustained-release treatments for retinal diseases, leveraging proprietary technology and strategic industry partnerships.
